A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

JN White Introduces the SnaggleClaw™

J.N. White Associates, Inc. (announced today that it is launching the SnaggleClaw™: a new multipurpose, touchless tool that limits exposure to pathogens.

The JN White ®  SnaggleClaw™is to be used in situations where an individual risks exposure to COVID-19.

This tool provides a safer alternative to touching in everyday activities, such as operating touchscreens, keypads and door handles. In addition, the tool contains an antimicrobial coating that offers an additional layer of defense against pathogens.

JN White® is an ISO 9001:2015 and ITAR-certified custom manufacturer specializing in the design and production of membrane switches, graphic overlays and custom labels. The company works with a wide range of global companies in many industries including military/DoD, medical devices and appliances. In response to the coronavirus pandemic, JN White® moved into the development and production of Personal Protective Equipment (PPE).

When asked why the firm continues to expand into new PPE products, JN White® President, Jason Aymerich, explains, “JN White® continues to innovate where the market has a need.  Providing solutions in the PPE space furthers the firm’s commitment to helping our country stay strong.”

SplatterGuard and SnaggleClaw are trademarks of J.N. White Associates, Inc. JN White and Precision Answers are registered trademarks of J.N. White Associates, Inc. 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy